1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Glutaminase

Glutaminase

Glutaminase is the initial enzyme in glutamine metabolism, which catalyzes the hydrolysis of glutamine to glutamate in cells. Glutaminase plays a key role in cancer cell metabolism, growth, and proliferation. In mammalian cells, there are two paralogous GLS genes, GLS1 (or GLS) and GLS2. GLS1 encodes two alternatively spliced isozymes: kidney glutaminase (KGA) and glutaminase C (GAC). GLS2 also encodes two isozymes: liver glutaminase (LGA) and glutaminase B.

GLS1 is ubiquitously expressed in various tissues, and its expression can be induced by the oncogene MYC. GLS1 is frequently activated and/or overexpressed in various types of cancer, including hepatocellular carcinoma (HCC). GLS1 has been reported to promote tumorigenesis in different types of cancer, including HCC, which is mainly attributable to its glutaminase activity and role in promoting glutamine metabolism. GLS has emerged as a critical enzyme in a number of cancer types. Elevated GLS2 enzymatic activity has also been correlated with tumor cell growth in vitro and in vivo. N-Myc activates GLS2 to promote conversion of glutamine to glutamate in MYCN-amplified neuroblastoma cells. Abrogation of GLS2 function profoundly inhibits glutaminolysis and dramatically decreases cell proliferation and survival in vitro and in vivo. However, there is controversy over the role of GLS2 as a tumor suppressor. Enzymatic activity independent of GLS2 is up-regulated via p53 or p63 and plays a role of tumor suppressor.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W006187
    2-Amino-2-(p-tolyl)acetic acid
    Inhibitor
    2-Amino-2-(p-tolyl)acetic acid is used for optimizing azide skeleton, and is the intermediate in the synthesis of 1,3, 4-thiadiazole compounds. 1,3,4-thiadiazole compounds exhibit potential anti-cancer activity, and inhibit glutaminase (GLSI).
    2-Amino-2-(p-tolyl)acetic acid
  • HY-144666
    GLS-1-IN-1
    Inhibitor 99.64%
    GLS-1-IN-1 (compound 1d) is a GLS-1 inhibitor. GLS-1-IN-1 shows inhibitory effect against Hep G2, MCF 7, and MCF 10A cells.
    GLS-1-IN-1
  • HY-160132
    TG-2-IN-4
    Inhibitor
    TG-2-IN-4 (compound 8) is a transglutaminase 2 (TG2) inhibitor with an IC50 <0.5 mM. TG-2-IN-4 can be used for the research of inflammatory disorder.
    TG-2-IN-4
  • HY-151434
    GLS1 Inhibitor-6
    Inhibitor
    GLS1 Inhibitor-6 (Compound 24y) is an orally active, potent and selective glutaminase 1 (GLS1) inhibitor (IC50=68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis.
    GLS1 Inhibitor-6
  • HY-12248A
    Telaglenastat hydrochloride
    Inhibitor
    Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity.
    Telaglenastat hydrochloride
  • HY-147718
    α-Glucosidase-IN-5
    Inhibitor
    α-Glucosidase-IN-5 (compound 8) is a potent α-glucosidase inhibitor with an IC50 of 57.9 µM. α-Glucosidase-IN-5 has the potential for the research of diabetes mellitus.
    α-Glucosidase-IN-5
  • HY-145933
    BJJF078
    Inhibitor
    BJJF078 is an aminopiperidine derivative. BJJF078 is a potent inhibitor of recombinant human and mouse Transglutaminase enzyme (TG2) activity, IC50 values of 41 and 54 nM, respectively. BJJF078 also inhibits the close related enzyme TG1, with an IC50 of 0.16 μM. BJJF078 can be used for Multiple sclerosis (MS) research.
    BJJF078
  • HY-102073
    TG53
    Inhibitor
    TG53 is a potent inhibitor of tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction. TG53 inhibits formation of a complex with integrin β1 and activation of FAK and c-Src during SKOV3 cell attachment onto FN. TG53 can be used for ovarian cancer research.
    TG53
  • HY-155138
    GLS1 Inhibitor-7
    Inhibitor
    GLS1 Inhibitor-7 (compound 4d) is a GLS1 inhibitor (IC50=46.7 μM), with potential anti-cancer, anti-aging and anti-obesity properties.
    GLS1 Inhibitor-7
  • HY-146616
    GLS1 Inhibitor-3
    Inhibitor
    GLS1 Inhibitor-3 (compound C147) is a potent GLS1 inhibitor with an IC50 of 27.98 nM. GLS1 Inhibitor-3 shows antiproliferative activity.
    GLS1 Inhibitor-3
  • HY-155102
    PROTAC TG2 degrader-2
    Degrader
    PROTAC TG2 degrader-2 (compound 7) is a selective, competitive degrader targeting Transglutaminase 2 (TG2), with Kd > 100 μM. PROTAC TG2 degrader-2 inhibits the cell migration and decreases the level of TG2 in ovarian cancer cells. PROTAC TG2 degrader-2 can be used for ovarian cancer study.
    PROTAC TG2 degrader-2
  • HY-146658
    Glutaminase-IN-4
    Inhibitor
    Glutaminase-IN-4 (compound 2a) is a glutaminase (GLS) inhibitor with an IC50 of 2.3 μM.
    Glutaminase-IN-4
  • HY-146617
    GLS1 Inhibitor-4
    Inhibitor
    GLS1 Inhibitor-4 (compound 41e) is a potent GLS1 inhibitor with an IC50 of 11.86 nM. GLS1 Inhibitor-4 shows antiproliferative activity, good metabolic stability, robust GLS1 binding affinity. GLS1 Inhibitor-4 blocks the glutamine metabolism and induce the production of ROS. GLS1 Inhibitor-4 induces apoptosis and shows antitumor activity.
    GLS1 Inhibitor-4
  • HY-152207
    LWG-301
    Inhibitor
    LWG-301 is an allosteric inhibitor of Glutaminase 1 (GLS1) with an IC50 value of 7 nM. LWG-301 significantly block glutamine metabolism, increases intracellular ROS, thus induces apoptosis. LWG-301 exhibits moderate antitumor effects in HCT116 xenograft model.
    LWG-301
  • HY-149602
    Glutaminase C-IN-2
    Inhibitor
    Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC50 of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects.
    Glutaminase C-IN-2
  • HY-148241
    A-446
    Inhibitor
    A-446 is a potent glutaminase (GLS) inhibitor with an IC50 value of 31 nM.
    A-446
  • HY-129126
    NC9
    Inhibitor
    NC9 (Cbz-Lys(Acr)-PEG2-dansyl) is an irreversible transglutaminase (TG) inhibitor. NC9 inhibits osteoblast differentiation and mineralization. NC9 destabilizes microtubules. NC9 can be used for the research of osteoblast differentiation.
    NC9
  • HY-155643
    PROTAC TG2 degrader-1
    Inhibitor
    PROTAC TG2 degrader-1 (compound 11) is a von Hippel-Lindau (VHL)-based PROTAC targeting tissue transglutaminase (TG2) with a KD of 68.9 μM. PROTAC TG2 degrader-1 reduces TG2 in ovarian cancer cells in a proteasome-dependent manner.
    PROTAC TG2 degrader-1
  • HY-N2916
    Barbinervic acid
    Inhibitor
    Barbinervic acid is a glutaminase inhibitor with an IC50 of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases.
    Barbinervic acid
  • HY-W020050S
    Cystamine-d8 (dihydrochloride)
    Cystamine-d8 (dihydrochloride) is the deuterium labeled Cystamine (dihydrochloride)[1]. Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD)[2][3][4].
    Cystamine-d<sub>8</sub> (dihydrochloride)
Cat. No. Product Name / Synonyms Application Reactivity